Projects per year
Personal profile
External positions
Post-Doctoral Fellow, Institut Curie Paris, UMR 144 CNRS, Department of Cell Morphogenesis and Tumor progression
2000 → 2003
Fingerprint
Dive into the research topics where Bassam Janji is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
INCEPTOR: Investigating the mode of action of ACB1801 on increasing TAP1 and improving cancer immunotherapy
Janji, B. (Scientific Advisor/Mentor) & Ramos, T. (PI)
1/04/24 → 31/03/26
Project: Research
-
CombiN (Elisabetta Bartolini): Improving the Therapeutic benefit of immunotherapy in Neuroblastoma by combining autophagy inhibitor and anti-PD-i
Janji, B. (PI) & Bartolini, E. (PhD Student)
1/02/23 → 31/01/27
Project: Research
-
-
Quantitative pre-clinical imaging of hypoxia and vascularity using MRI and PET
Kanli, G., Boudissa, S., Jirik, R., Adamsen, T., Espedal, H., Rolfsnes, H. O., Thorsen, F., Pacheco-Torres, J., Janji, B. & Keunen, O., 15 Jan 2025, Immuno-Oncology and Immunotherapy - Part C. Bloy, N., Charpentier, M. & Galluzzi, L. (eds.). Academic Press Inc., Vol. 191. p. 289-328 40 p. (Methods in Cell Biology; vol. 191).Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review
2 Citations (Scopus) -
Targeting the atypical chemokine receptor 2 (Ackr2) improves the benefit of anti-PD-1 immunotherapy in melanoma mouse model
Noman, M. Z., Szpakowska, M., Xiao, M., Gao, R., Van Moer, K., Kumar, A., Ollert, M., Berchem, G., Chevigné, A. & Janji, B., 18 Apr 2025, In: OncoImmunology. 14, 1, 9 p., 2494426.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
Atypical chemokine receptor 2 expression is directly regulated by hypoxia inducible factor-1 alpha in cancer cells under hypoxia
Benoit, A., Lequeux, A., Harter, P., Berchem, G. & Janji, B., 4 Nov 2024, In: Scientific Reports. 14, 1, 26589.Research output: Contribution to journal › Article › Research › peer-review
Open Access2 Citations (Scopus) -
Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti-tumor efficacy
Yu, Y., Bogdan, M., Noman, M. Z., Parpal, S., Bartolini, E., Van Moer, K., Kleinendorst, S. C., Bilgrav Saether, K., Trésaugues, L., Silvander, C., Lindström, J., Simeon, J., Timson, M. J., Al-Hashimi, H., Smith, B. D., Flynn, D. L., Alexeyenko, A., Viklund, J., Andersson, M. & Martinsson, J. & 3 others, , Aug 2024, In: Molecular Oncology. 18, 8, p. 1904-1922 19 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access6 Citations (Scopus) -
Improving STING agonist-based cancer therapy by inhibiting the autophagy-related protein VPS34
Bartolini, E., Van Moer, K. & Janji, B., 11 Jun 2024, In: OncoImmunology. 13, 1, 2364958.Research output: Contribution to journal › Letter › peer-review
Open Access4 Citations (Scopus)